Putting GSK’s China Bribery Crisis In Context
This article was originally published in PharmAsia News
Executive Summary
GSK’s China bribery crisis stems in part from a poorly managed and financed public-hospital system that relies on drug sales and markups to survive. The question is, will the government make reforms soon enough, and what should companies do in the meantime?